Home

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s Disease drug development. We are developing innovative therapeutics with “best in class” potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody for passive immunization is partnered with Genentech and entered Phase I in 2008. We continue to develop in house the small molecule ACI-91 which entered Phase II in 2008 and the vaccine ACI-24 which entered Phase I in 2009. These three clinical programs are focused on Alzheimer’s Disease, and are backed by a rich portfolio of preclinical compounds. Our therapeutic molecules are also leveraged for Alzheimer´s Disease diagnostic and other central nervous system (CNS) and non-CNS diseases, such as Glaucoma.

Since its foundation in 2003, the company has raised CHF 64 million from private investors. The out-licensing agreement with Genentech was closed at the end of 2006 for a potential value of more than US$ 300 million. Our team of more than 35 professionals is based on the site of the Ecole Polytechnique Federale (EPFL) in Lausanne, Switzerland.

AC Immune Company Portrait (click to watch the video)